Finally, as BiP expression frequently correlates with tumor status, chemoresistance, and prognosis (Lee and Hendershot 2006; Wang and Kaufman 2014) and as ATF6α is the primary driver of BiP expression, targeting BiP expression via the ATFT6α pathway should be considered a therapeutic approach for cancer (Gutierrez and Simmen 2014; Obacz et al. 2017). This evidence concerns the gene HSPA5 and cancer.